Emrusolmin
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Emrusolmin
- Molecular weight
- 343.18
- Structure (SMILES)
- Brc1cccc(-c2cc(-c3ccc4c(c3)OCO4)n[nH]2)c1
- anle 138b
- ANLE-138B
- anle138b
- Anle138b
- anle138b (TEV-56286)
- emrusolmin
- Emrusolmin
- emrusolmin [INN]
- emrusolmin inn
- emrusolmina
- Emrusolmina
- emrusolmine
- Emrusolmine
- CAS registry numbers
- 882697-00-9
- ChEMBL ID
- CHEMBL4748063
- InChIKey
- RCQIIBJSUWYYFU-UHFFFAOYSA-N
- PubChem compound IDs
- 44608289
- FDA ingredient codes (UNII)
- E7WRA77JET
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -solmin
Investigated indications
- Condition
- Parkinson Disease
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0005180
- Subject identifier
- D010300
- Condition identifier
- MONDO_0005180
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0007803
- Highest recorded phase
- 2
Trial references
- NCT04685265
- Hydrogen bond acceptors
- 3
- Hydrogen bond donors
- 1
- Polar surface area
- 47.14
- Calculated partition coefficient (ALogP)
- 4.23
- Calculated partition coefficient (XLogP)
- 4
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 2
- Heavy atoms
- 21
- Molecular formula
- C16H11BrN2O2
- Monoisotopic mass
- 342.00039
- Natural product
- Yes
- Recorded assays
- 65
- Active assays
- 1
Active assay types
- Confirmatory
Related records
Trials (8)
- A Drug-Drug Interaction Study to Assess the CYP1A2 and CYP3A4 Interaction Potential of TEV-56286 (anle138b)
- A First-in-Human Study of Single and Multiple Doses of anle138b in Healthy Subjects
- A Study to Assess New Formulations of TEV-56286
- A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of anle138b in Parkinson's Disease
- A Trial to Assess TEV-56286 at Different Doses in Healthy Participants
- A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy
- An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy
- Mass Balance Clinical Trial With TEV-56286
In development for (1)
- Parkinson disease Phase 1